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OBJECTIVES We sought to compare the short-term impact of three different phosphodiesterase-5 (PDE5)
inhibitors on pulmonary and systemic hemodynamics and gas exchange parameters in patients
with pulmonary arterial hypertension (PAH).
BACKGROUND The PDE5 inhibitor sildenafil has been reported to cause pulmonary vasodilation in patients
with PAH. Vardenafil and tadalafil are new PDE5 inhibitors, recently being approved for the
treatment of erectile dysfunction.
METHODS Sixty consecutive PAH patients (New York Heart Association functional class II to IV) who
underwent right heart catheterization received short-term nitric oxide (NO) inhalation and
were subsequently assigned to oral intake of 50 mg sildenafil (n  19), 10 mg (n  7) or 20
mg (n  9) vardenafil, or 20 mg (n  9), 40 mg (n  8), or 60 mg (n  8) tadalafil.
Hemodynamics and changes in oxygenation were assessed over a subsequent 120-min
observation period.
RESULTS All three PDE5 inhibitors caused significant pulmonary vasorelaxation, with maximum effects
being obtained after 40 to 45 min (vardenafil), 60 min (sildenafil), and 75 to 90 min
(tadalafil). Sildenafil and tadalafil, but not vardenafil, caused a significant reduction in the
pulmonary to systemic vascular resistance ratio. Significant improvement in arterial oxygen-
ation (equally to NO inhalation) was only noted with sildenafil.
CONCLUSIONS In PAH patients, the three PDE5 inhibitors differ markedly in their kinetics of pulmonary
vasorelaxation (most rapid effect by vardenafil), their selectivity for the pulmonary circulation
(sildenafil and tadalafil, but not vardenafil), and their impact on arterial oxygenation
(improvement with sildenafil only). Careful evaluation of each new PDE5 inhibitor, when
being considered for PAH treatment, has to be undertaken, despite common classification as
PDE5 inhibitors. (J Am Coll Cardiol 2004;44:1488–96) © 2004 by the American College
of Cardiology Foundation(
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en recent years, several new drugs have been developed for
he treatment of pulmonary arterial hypertension (PAH),
ncluding continuous intravenous epoprosterenol (1), in-
aled iloprost (2), subcutaneous trepostinil (3), oral bosen-
an (4), and oral beraprost (5,6). In addition, there is
ncreasing evidence for the therapeutic effectiveness of the
hosphodiesterase-5 (PDE5) inhibitor sildenafil in PAH
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ccepted June 7, 2004.7–9). Phosphodiesterases are a superfamily of enzymes that
nactivate cyclic adenosine monophosphate and cyclic
uanosine monophosphate, the second messengers of pros-
acyclin and nitric oxide (NO) (Fig. 1). The phosphodies-
erases have different tissue distributions and substrate
ffinities (10). Interestingly, PDE5 is abundantly expressed
n lung tissue (11), thus offering as target molecule for PAH
reatment concepts.
Recently, the new PDE5 inhibitors vardenafil and
adalafil have been approved for the treatment of erectile
ysfunction. These PDE5 inhibitors share major properties
ith sildenafil, including mechanisms of action and prefer-
ntial though not fully selective inhibition of PDE5. The
linical efficacy and safety profiles of these medications are
inked to their molecular mode of action, their selectivity for
DE5, and their pharmacokinetic properties (12). How-
ver, all investigations performed so far have mainly focused
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October 6, 2004:1488–96 Comparison of PDE5 Inhibitors in PAHn comparing the effects of these substances on erectile
ysfunction. No data exist addressing the efficacy and safety
f vardenafil and tadalafil, as opposed to sildenafil, on
ulmonary and systemic hemodynamics in patients with
AH.
In the present study, we characterized the hemodynamic
rofile of different doses of vardenafil and tadalafil in
atients with PAH. Response profiles were compared with
hose of inhaled NO (20 to 40 ppm) and sildenafil (50 mg),
erving as reference agents, as previously described
7,9,13,14). Dosing of vardenafil and tadalafil was based on
he labeling of these substances in their original indication,
s well as preliminary investigations of our own group (data
ot published) addressing dose-response profiles of these
gents.
Abbreviations and Acronyms
cGMP  cyclic guanosine monophosphate
CI  confidence interval
mPAP  mean pulmonary arterial pressure
NO  nitric oxide
NYHA  New York Heart Association
PAH  pulmonary arterial hypertension
PDE  phosphodiesterase
PVRI  pulmonary vascular resistance index
SVRI  systemic vascular resistance index
igure 1. Intracellular signaling pathway of nitric oxide (NO), prostanoids,
trial natriuretic peptide [ANP], brain natriuretic peptide [BNP], and pros
yclases generate cyclic guanosine monophosphate (cGMP) and adenosin
essengers, via activation of protein kinases, induce cellular responses (i.e.
igands by degradation of second messengers cGMP and cAMP into ina
ugment and prolong the cellular responses to NO, prostanoids, and natriureticETHODS
atients. Overall, 82 patients were screened, of whom 22
ere excluded (12 did not meet inclusion criteria, seven did
ot provide consent, and three were clinically unstable
etween screening and study onset). Sixty patients (39
omen and 21 men) with chronic PAH, as defined by the
ecent World Conference on Pulmonary Hypertension (15),
ere included: 46 with idiopathic PAH, seven with Eisen-
enger’s disease, four with CREST (calcinosis cutis,
aynaud phenomenon, esophageal dysfunction, sclerodac-
yly, and telangiectasia), two with porto-pulmonary hyper-
ension, and one with human immunodeficiency virus
ssociated.
All patients were admitted to our pulmonary hyperten-
ion center for testing of pulmonary vasoreactivity and
valuation of therapeutic options. Diagnostic procedures
receding patient recruitment included clinical chemistry,
mmunologic analysis, chest X-ray, lung function testing,
chocardiography, and a high-resolution computed tomo-
raphic scan of the lung. In all cases, perfusion scintigraphy,
piral computed tomography, and, in selected cases, pulmo-
ary angiography were performed to exclude chronic throm-
oembolism as the underlying reason for pulmonary hyper-
ension. All patients were tested for the first time and had
ot been previously treated with pulmonary vasodilators,
xcept for 14 of the patients receiving low-dose calcium
hannel blocker therapy.
atriuretic peptides: role of phosphodiesterases (PDEs). Ligands (i.e., NO,
s) activate membrane-bound or soluble cyclases. Guanylate and adenylate
nophosphate (cAMP) from GTP and ATP. These intracellular second
dilation and anti-proliferation). Phosphodiesterases limit the effects of the
GMP and AMP. Thus, by inhibition of the PDEs, the PDE inhibitorsand n
tanoid
e mo
, vaso
ctivepeptides.
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Comparison of PDE5 Inhibitors in PAH October 6, 2004:1488–96Exclusion criteria were pulmonary hypertension second-
ry to chronic obstructive or restrictive pulmonary disease,
ecurrent pulmonary embolism, pulmonary venous conges-
ion, acute or chronic inflammatory lung disease, pregnancy
r insufficient contraceptive measures, and previous treat-
ent with PDE inhibitors. The individual response to
asodilators, including inhaled NO, was neither an inclu-
ion nor an exclusion criterion. The study protocol was
pproved by the Justus-Liebig-University Ethics Commit-
ee, and each patient gave written, informed consent. The
rocedures followed were in accordance with institutional
uidelines.
A fiberoptic thermodilution pulmonary artery catheter
Edwards Swan-Ganz, 93A-754H 7.5-F; Baxter Health-
are, Irvine, California) was used to measure central venous
ressure, pulmonary artery pressure, pulmonary artery
edge pressure, cardiac output, and mixed venous oxygen
aturation. Patients received continuous nasal oxygen
hroughout the entire test procedure if initial arterial oxygen
aturation was below 88%.
reatment. After assessment of baseline hemodynamic
alues, each patient received short-term inhaled NO; the
aximum vasodilator response to this agent required 20 to
0 ppm NO. When hemodynamic parameters had returned
o baseline values after cessation of NO inhalation, patients
eceived one oral dose of a PDE5 inhibitor. In the first 19
atients presenting with PAH, 50 mg sildenafil was orally
dministered. Subsequently, PAH patients were randomly
ssigned to receive either 10 mg (n  7) or 20 mg (n  9)
ral vardenafil or 20 mg (n  9), 40 mg (n  9), or 60 mg
n  8) oral tadalafil (Fig. 2). Patients were assigned to the
herapeutic regimens by using computerized randomization
n groups of five; no more than two patients in a row were
ssigned to one group. Hemodynamic measurements were
erformed at baseline, during maximum effect of inhaled
O, and 15, 30, 45, 60, 90, and 120 min (and, in selected
ases, after 150 min) after ingestion of each PDE5 inhibitor.
alculations were made at peak reduction of pulmonary
ascular resistance (PVR).
tatistics. All baseline data are given as the median and
ange (minimum to maximum). Hodges-Lehmann point
stimates of median difference and exact 95% confi-
ence intervals (CIs) are presented for the response of
ach parameter to each vasodilator challenge (pre- and
ost-intervention values). One-way analysis of variance
ith the Scheffé post-test for multiple comparisons was
sed to seek for statistical differences between hemody-
amic and gas exchange variables in the different treat-
ent groups at baseline and to analyze for statistical
ifferences regarding the responsiveness to each
asodilator.
ole of funding source. The sponsor of the study had no
ole in study design, data collection, data analysis, data
nterpretation, or writing of the report. sESULTS
unctional classification and baseline hemodynamics. Ac-
ording to clinical criteria, nine patients were classified as
eing in New York Heart Association (NYHA) functional
lass II, 35 patients in class III, and 16 patients in class IV.
he mean pulmonary artery pressure (mPAP) was markedly
levated (53.0 mm Hg [range 30 to 87 mm Hg]), and the
ardiac index was in the lower normal range (2.2 l/min per
2 [range 1.0 to 4.0 l/min per m2]), with a correspondingly
ncreased PVRI (PVRI 1,569 dynes/cm5 per m2 [range
02 to 4,099]). Distribution to functional classes, to PAH
ubgroups, as well as baseline hemodynamics did not sig-
ificantly differ between the treatment groups (Table 1).
itric oxide inhalation. Inhalation of NO caused a rapid
ecrease in mPAP by 9.8% (CI 7.2 to 13.4), accom-
anied by a median increase in the cardiac index by 6.0%
CI 2.6 to 9.4), resulting in a PVRI reduction of 15.5%
CI11.0 to19.3) (Table 2, Fig. 3). Pulmonary selectivity
f the vasodilatory effect was reflected by a reduction of
13.8% (CI 10.5 to 17.9) in the PVR/systemic vascular
esistance (SVR) ratio. Concomitantly, a significant increase in
rterial pO2 of 9.6% (CI 1.6 to 19.0) was noted. All NO-
nduced changes returned to baseline within 10 min after
topping inhalation of this agent.
ildenafil. Fifty mg of oral sildenafil caused a significant
ecrease of mPAP by 16.2% (CI 11.6 to 21.5),
ccompanied by a median increase in the cardiac index by
3.2% (CI 9.9 to 17.1), resulting in a PVRI reduction of
28.0% (CI 26.1 to 31.2) (Fig. 3). A peak vasodilatory
ffect was noted at 60 min (CI 52.0 to 67.5) after drug
ntake (Fig. 4). Despite systemic administration, pulmonary
electivity of the vasodilatory effect was reflected by a
15.5% (CI 11.1 to 21.3) reduction in the PVR/SVR
atio. As with inhaled NO, a concomitant significant
ncrease in arterial pO2 of 8.9% (CI 1.2 to 22.9) was noted.
o adverse events were reported during this short-term
asodilatory testing procedure on intake of sildenafil.
ardenafil. Oral vardenafil at doses of 10 mg and 20 mg
aused a significant decrease of mPAP of14.3% (CI5.6
o 23.1) and 12.1% (CI 7.3 to 15.8), respectively. A
edian increase in the cardiac index of 9.3% (CI 1.8 to
8.7) was noted after 10 mg vardenafil and of 18.4% (CI 9.8
o 25.1) after 20 mg vardenafil, respectively. The PVRI was
educed by 21.6% (CI 10.2 to 32.3) and 26.3 (CI
22.8 to 29.2), respectively (Fig. 3). Peak vasodilatory
ffect was noted at 41.3 min (CI 22.5 to 60.0) after intake
f 10 mg vardenafil and at 45 min (CI 37.5 to 60.0) of 20
g vardenafil (Fig. 4). By contrast with inhaled NO and
ral sildenafil, vardenafil caused almost an equipotent re-
uction of SVR and PVR, as reflected by the PVR/SVR
atios of 6.9 (CI 24.8 to 15.2) for 10 mg and 0.1 (CI
8.2 to 4.2) for 20 mg of this substance. Arterial oxygen-
tion remained virtually unchanged with both concentra-
ions of this agent (Fig. 3). Despite the lack of pulmonary
electivity, only minor adverse events (such as flushing and
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October 6, 2004:1488–96 Comparison of PDE5 Inhibitors in PAHlight headache in three of nine patients in the 20-mg
roup) were reported after intake of vardenafil.
adalafil. Oral tadalafil, given at doses of 20, 40, and 60
igure 2. Hemodynamic and oxygenation response to inhaled nitric oxid
re-intervention baseline value are displayed (point estimates of median dif
bars] for inhaled NO [NO 20 to 40 ppm  solid circles], oral sildenafil [
0 mg  blue diamonds], and 20, 40, and 60 mg oral tadalafil [Tada 20
ystemic arterial pressure; CI  cardiac index; pO2  partial pressure of a
s determined by one-way analysis of variance. ¶Different from NO. Difg, caused a significant decrease of mPAP of 12.6% CI 3.6 to 24.4), 18.3% (CI 13.9 to 21.8), and
10.0% (CI 22.2 to 1.1), respectively. Median increases
n the cardiac index of 9.3% (CI 4.8 to 15.4), 7.5% (CI
), oral sildenafil, oral vardenafil, and oral tadalafil. Deviations from the
e [percentage of baseline  symbols], with exact 95% confidence intervals
mg  red squares], 10 and 20 mg oral vardenafil [Vard 10 mg and Vard
Tada 40 mg, Tada 60 mg  green inverted triangles]). mSAP  mean
oxygen. The p values indicate significant differences of treatment effects,
from tadalafil 60 mg (p  0.05, Scheffé post-test).e (NO
ferenc
Sil 50
mg,
rterial
ferent4.0 to 20.7), and 18.8% (CI 3.3 to 36.7) were noted for
Table 1. Baseline Hemodynamic and Gas Exchange Variables
Treatment Group
Baseline/NO
(n  60)
Sildenafil
50 mg
(n  19)
Vardenafil
10 mg
(n  7)
Vardenafil
20 mg
(n  9)
Tadalafil
20 mg
(n  9)
Tadalafil
40 mg
(n  8)
Tadalafil
60 mg
(n  8)
p
Value*
Age (yrs) 51
(18 to 81)
54
(18 to 81)
46
(37 to 78)
51
(31 to 74)
42
(28 to 67)
64
(33 to 70)
44
(39 to 69)
0.334
PAH origin, A/B/C/D/E 46/7/4/2/1 14/4/0/0/1 5/2/0/0/0 7/0/0/2/0 7/0/2/0/0 6/1/1/0/0 7/0/1/0/0 NA
Patients receiving oxygen (n) 30 10 3 4 4 5 4 NA
NYHA class distribution, II/III/IV 10/34/16 0/12/7 2/4/1 3/5/1 1/4/4 2/6/0 2/3/3 0.121
Heart rate (beats/min) 82
(55 to 108)
83
(63 to 96)
76
(62 to 107)
90
(72 to 108)
82
(61 to 105)
69
(55 to 89)
81
(57 to 106)
0.105
Mean systemic arterial pressure
(mm Hg)
88
(64 to 140)
95
(79 to 125)
78
(74 to 110)
86
(70 to 123)
91
(77 to 140)
86
(64 to 99)
90
(76 to 116)
0.331
Mean pulmonary arterial pressure
(mm Hg)
53
(30 to 87)
56
(43 to 74)
61
(31 to 87)
48
(30 to 79)
45
(31 to 84)
48
(31 to 55)
46
(36 to 78)
0.233
Cardiac index (l/min per m2) 2.2
(1.0 to 4.0)
2.1
(1.0 to 3.5)
2.9
(1.8 to 4.0)
2.4
(1.7 to 3.9)
2.0
(1.2 to 2.8)
2.1
(1.8 to 2.6)
2.5
(1.0 to 3.8)
0.116
Systemic vascular resistance index
(dynes/cm5/m2)
3,222
(1,463 to 6,316)
3,854
(1,728 to 6,316)
1,860
(1,737 to 4,303)
2,735
(1,463 to 5,158)
3,383
(2,235 to 3,337)
2,735
(2,458 to 3,328)
2,555
(1,929 to 4,150)
0.038
Pulmonary vascular resistance index
(dynes/cm5/m2)
1,569
(402 to 4,098)
1,811
(949 to 4,098)
1,369
(586 to 3,280)
1,647
(402 to 2,659)
1,336
(753 to 3,337)
1,303
(750 to 1,969)
1,011
(572 to 3,986)
0.212
Mixed venous oxygen saturation (%) 62.9
(30.7 to 81.1)
60.5
(44.2 to 71.8)
68.3
(61.8 to 72.6)
62.5
(49.1 to 72.3)
65.8
(39.9 to 81.1)
61.1
(51.4 to 78.8)
61.4
(30.7 to 74.6)
0.265
Partial pressure of arterial oxygen
(mm Hg)
69.9
(47.8 to 166.0)
70.5
(50.0 to 147.0)
76.7
(49.0 to 82.0)
68.5
(56.3 to 135.7)
81.0
(54.0 to 166.0)
62.8
(47.8 to 101.0)
66.1
(64.0 to 72.3)
0.330
Partial pressure of carbon monoxide
(mm Hg)
33.3
(22.0 to 59.4)
29.5
(23.6 to 40.0)
38.4†
(29.4 to 55.7)
34.0
(29.7 to 37.9)
35.7
(23.5 to 59.4)
33.2
(22.0 to 39.0)
34.2
(27.8 to 41.0)
0.007
*Analysis of variance was used to seek significant intergroup variances. †Different from sildenafil 50 mg group (p  0.05, Scheffé post-test). Hemodynamic and gas exchange variables at baseline for the entire patient population
(baseline/NO) and for the subgroups (after assignment to different treatments) are presented in this table. Data are presented as the median value (range) or number of subjects.
NA  not applicable; NO  nitric oxide; NYHA  New York Heart Association; PAH  pulmonary arterial hypertension; PAH origin: A  idiopathic pulmonary arterial hypertension; B  Eisenmenger’s disease; C  CREST
syndrome; D  porto-pulmonary hypertension; E  HIV associated.
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Table 2. Peak Effects of Pharmacologic Interventions on Hemodynamics and Gas Exchange Variables
Treatment Group
Baseline/NO
(n  60)
Sildenafil
50 mg
(n  19)
Vardenafil
10 mg
(n  7)
Vardenafil
20 mg
(n  9)
Tadalafil
20 mg
(n  9)
Tadalafil
40 mg
(n  8)
Tadalafil
60 mg
(n  8)
p
Value*
Heart rate (beats/min) 0.6
(1.6 to 2.9)
4.9
(10.3 to 0.1)
4.2
(6.3 to 22.1)
4.4
(3.4 to 8.8)
5.4
(17.9 to 7.6)
1.2
(7.7 to 14.4)
3.1
(7.7 to 14.8)
0.06
Mean systemic arterial pressure
(mm Hg)
2.6†‡
(0.8 to 4.2)
6.9§
(4.5 to 8.8)
6.9
(17.1 to 1.5)
12.1§#
(8.1 to 16.9)
6.9†
(0.8 to 16.1)
7.3†
(0.9 to 14.4)
1.1
(8.6 to 8.5)
0.0001
Mean pulmonary arterial pressure
(mm Hg)
9.8§
(7.2 to 13.3)
16.2§
(11.6 to 21.4)
14.3§
(5.6 to 23.1)
12.1§
(7.3 to 15.8)
12.6†
(2.8 to 24.4)
18.3§
(13.3 to 21.8)
10.0
(22.2 to 2.0)
0.241
Cardiac index (l/min per m2) 6.0†
(2.6 to 9.4)
13.2§
(10.0 to 17.1)
9.3†
(1.8 to 18.7)
18.4§
(9.8 to 25.1)
9.4
(4.8 to 15.4)
7.5
(4.0 to 20.7)
18.8†
(3.3 to 36.7)
0.142
Systemic vascular resistance index
(dynes/cm5/m2)
1.2
(4.3 to 2.3)
14.3§¶
(11.0 to 18.2)
14.8§
(7.1 to 28.0)
26.4¶§
(17.5 to 29.9)
11.5
(25.0 to 3.1)
14.0
(0.3 to 22.7)
12.0
(25.6 to 2.0)
0.0001
Pulmonary vascular resistance index
(dynes/cm5/m2)
15.5§
(11.0 to 19.3)
28.0§¶
(26.1 to 31.1)
21.6§
(10.2 to 32.3)
26.3§
(22.8 to 29.2)
18.6§
(14.4 to 28.4)
27.1§
(14.2 to 39.8)
26.7§
(19.9 to 39.8)
0.002
PVR/SVR ratio 13.8§
(10.2 to 18.0)
15.5§
(11.1 to 21.2)
6.9
(24.8 to 15.2)
0.1
(8.2 to 4.2)
9.3
(26.5 to 14.9)
16.0§
(7.1 to 26.1)
11.5
(2.8 to 33.9)
0.151
Mixed venous oxygen saturation
(%)
3.6†
(1.7 to 5.8)
8.4§
(4.4 to 13.0)
4.8
(0.2 to 9.7)
6.1
(0.8 to 21.2)
0.7
(6.9 to 12.0)
0.6
(3.5 to 5.1)
4.6
(1.1 to 23.2)
0.465
Partial pressure of arterial oxygen
(mm Hg)
9.6†
(1.6 to 19.0)
8.9
(1.2 to 22.9)
2.6
(11.4 to 22.5)
2.2
(17.9 to 13.5)
3.2
(12.3 to 12.5)
3.9
(11.6 to 9.6)
1.7
(10.1 to 4.5)
0.475
Partial pressure of carbon monoxide
(mm Hg)
0.6
(1.1 to 2.1)
2.2
(1.1 to 5.2)
3.3
(0.1 to 6.4)
0.9
(5.4 to 3.8)
0.2
(3.4 to 3.5)
0.0
(10.0 to 3.1)
1.7
(6.2 to 1.0)
0.882
Hemodynamic and gas exchange variables at baseline for the entire patient population (baseline/NO) and for the subgroups (after assignment to different treatments) are presented in this table. *Analysis of variance was used to seek
significant intergroup variances. Symbols indicate significant differences for each variable as compared with pre-intervention baseline values: †p  0.01; §p  0.001; p  0.05. ‡Different from all groups except tadalafil 60 mg. #Different
from tadalafil 60 mg. ¶Different from NO (p  0.05, Scheffé post-test). Data are presented as the median value (range).
NO  nitric oxide; PVR/SVR  pulmonary to systemic vascular resistance.
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Comparison of PDE5 Inhibitors in PAH October 6, 2004:1488–960, 40, and 60 mg of tadalafil. The PVRI was reduced by
18.6% (CI 14.0 to 28.4), 27.1% (CI 14.2 to
39.8), and 26.7 (CI 19.9 to 39.8), respectively (Fig.
). A peak vasodilatory effect was noted at 75 min (CI 52.5
o 120) after intake of 20 mg, at 90 min (CI 60 to 120) with
0 mg, and at 86.3 min (CI 52.5 to 135) with 60 mg of
adalafil, respectively (Fig. 4). Interestingly, even at the
igure 3. Kinetics of peak pulmonary vasodilatory effects of the different
hosphodiesterase-5 (PDE5) inhibitors. Deviations from the pre-
ntervention baseline values (point estimates of median difference [percent-
ge of baseline  symbols], with exact 95% confidence intervals [CIs]
vertical bars]) for PVRI over time; also displayed are point estimates of
edian difference effects (percentage of baseline  symbols), with exact
5% CIs (horizontal bars). The changes are noted in response to sildenafil
Sil 50 mg  red square), vardenafil (Vard 10 mg  solid blue diamond;
ard 20 mg  open blue diamond), and tadalafil (Tada 20 mg  green
ourglass; Tada 40 mg  open green inverted triangle; Tada 60 mg 
olid green inverted triangle). The p value indicates significant difference
f time to peak pulmonary vasodilation between the different therapeutic
gents, as determined by analysis of variance (#different from Tadalafil 40
g group; p  0.05, Scheffé post-test). There was no difference in the
agnitude of response among the treatment groups (p  0.185). PVRI 
ulmonary vascular resistance index.
igure 4. Flow chart of participants. The design of the study and
ssignment of subjects to the therapeutic interventions are shown in thisuow chart.ighest dosage of 60 mg tadalafil, selectivity for the pulmo-
ary circulation was reflected by a significant reduction of
he PRV/SVR ratio of 11.4% (CI 2.8 to 33.9). As
ith oral vardenafil, arterial oxygenation remained virtually
nchanged with all concentrations of tadalafil employed
Fig. 3). No adverse events were reported after intake of oral
adalafil.
ISCUSSION
ur data show that despite sharing structural and pharma-
ologic similarities with sildenafil, vardenafil and tadalafil
iffer substantially from sildenafil in their effects on the
ulmonary circulation.
Lung tissue is a rich source of phosphodiesterases, in-
luding PDE5, the major function of which is acceleration
f the decay of cyclic guanosine monophosphate (cGMP)
11). Thereby, PDE5 limits the vasodilatory effects of
uanylate cyclase stimuli, such as NO and atrial natriuretic
eptides (10). Inhaled NO is a widely accepted vasodilatory
gent frequently used for the assessment of pulmonary
ascular reactivity in patients with chronic pulmonary hy-
ertension (16,17). The rate of so-called responders to this
gent (definition for response: fall in mPAP and PVRI of
ore than 20%; 11 of 60 patients in the current study) is
ell in line with previously published reports (13,14).
We and others recently showed that the PDE5-selective
nhibitor sildenafil causes strong and dose-dependent pul-
onary vasodilation (7–9). Notably, even at the high dose
f 50 mg sildenafil, the characteristics of preferential pul-
onary over systemic vasodilation were found to be pre-
erved in those preceding studies. Based on these results, we
mployed 50 mg oral sildenafil as a reference agent in the
urrent study. The profile of preferential pulmonary vaso-
ilation was well reproduced, with a maximum PVRI
eduction of 30% and a reduction of PVRI/SVRI ratio of
15% (Fig. 3). At the time being, our best explanation for
he preferential pulmonary vasodilatory effect of sildenafil
erives from the assumption of a substantial baseline stim-
lation of guanylate cyclase in the lung vasculature of
atients with chronic pulmonary hypertension, attributable
o ongoing pulmonary NO production (18–20) and to
irculating natriuretic peptides such as atrial and brain
atriuretic peptide (21–23).
Most interestingly, sildenafil not only displays character-
stics of pulmonary selectivity but also appears to ameliorate
entilation-perfusion matching (“intrapulmonary selectiv-
ty”), thereby improving arterial oxygenation. This has
reviously been shown in patients with lung fibrosis and
econdary pulmonary hypertension, in whom sildenafil si-
ultaneously reduced PVR and improved gas exchange
roperties (24). In the currently tested patients, ventilation-
erfusion matching was not directly assessed, but intrapul-
onary selectivity of sildenafil is again indicated by a
ignificant increase of arterial oxygenation. It may be spec-
lated that sildenafil does not act as a nonspecific vasodilator
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October 6, 2004:1488–96 Comparison of PDE5 Inhibitors in PAHn this vascular bed, but rather amplifies local cGMP-based
asoregulatory loops, thereby improving rather than disturb-
ng adaptation of perfusion to ventilation distribution.
The newly introduced PDE5 inhibitors vardenafil and
adalafil have both been reported to be equally effective as
ildenafil with regard to the treatment of erectile dysfunc-
ion (25,26). The main differences described so far are
elated to the rapidity of the onset of effects and to the
uration of effects. Furthermore, several reports indicate a
lightly different side-effect profile of vardenafil, tadalafil,
nd sildenafil (27–29). Currently, most authors explain
hese differences by the different selectivities of sildenafil,
ardenafil, and tadalafil for the various PDE subgroups:
ildenafil’s 50% inhibitory capacity values for PDE5 (3.5
mol), PDE6 (37 nmol), PDE1 (281 nmol), and PDE11 A
2,730 nmol) indicate a high selectivity for PDE5, but not
n exclusive effect on this PDE (25). Similarly, vardenafil’s
electivity for PDE5 over PDE6, PDE1, and PDE11 A is
5-fold, 500-fold, and 1,160-fold, respectively. By contrast,
adalafil is considerably more selective for PDE5 than for
DE6 (187-fold) but has significantly less selectivity for
DE11 A (fivefold selectivity for PDE5 over PDE11 A). In
ddition, there are major differences in mean half-lives: 3 to
h for sildenafil and vardenafil (30) and 18 h for tadalafil
31).
Our current observations regarding peak hemodynamic
ffects being reached after 40 min with vardenafil, 60
in with sildenafil, and 90 min with tadalafil are well in
greement with previous reports addressing kinetics of
ffects in the erectile dysfunction area (31). However,
espite sharing many similarities with sildenafil in terms of
tructure and pharmacologic properties, vardenafil was
ound to lack pulmonary selectivity in our currently inves-
igated patient cohort. This observation was true for both
he 10-mg and 20-mg vardenafil group, as indicated by
irtually equivalent reductions of PVR and SVR in response
o both dosages. Further studies are needed to address the
uestion of whether this surprisingly different profile, as
ompared with sildenafil, is due to the minor differences in
he PDE inhibition pattern or to PDE’s unrelated, currently
nknown modes of actions.
Tadalafil is currently approved for the treatment of
rectile dysfunction in dosages of 10 mg and 20 mg per
ablet (32). However, in studies investigating the effects of
adalafil on cardiac and circulatory function, single doses up
o 50 mg have been reported to be safe in terms of an
bsence of significant systemic vasodilation (33). In preced-
ng pilot studies in PAH patients (data not given), up to 60
g tadalafil was found to be well tolerated, without major
ystemic side effects. Based on these data, we decided to use
0, 40, and 60 mg of oral tadalafil in the current investiga-
ion in a randomized fashion. Most interestingly, tadalafil
isplayed selectivity for the pulmonary circulation, even in
he 60-mg group. As expected from previous pharmacoki-
etic data, the peak hemodynamic effects of tadalafil were
oted after90 min. We have not extended the observationeriod over 120 min (and in selected cases up to 150 min),
s the entire catheterization and vasoreactivity testing pro-
edure exceeded 6 h on average. Pharmacokinetic studies
haracterizing the maximum duration of PDE5 effects will
e subject to forthcoming investigations.
By contrast with inhaled NO and sildenafil, neither
ardenafil nor tadalafil improved arterial oxygenation. As
ultiple inert gas elimination measurements were not
erformed in the present study, the underlying mechanisms
ay not be fully resolved. There was no difference in cardiac
utput increase between sildenafil on the one side and both
ardenafil and tadalafil on the other, and it is thus highly
nlikely that differences in central venous oxygen saturation
re responsible for the differences in arterial oxygenation.
hus, it may be assumed that sildenafil, as mentioned
arlier, exerted a favorable impact on ventilation-perfusion
atching, but this was not the case for vardenafil and
adalafil. It is presently fully unknown whether the discussed
ifferences in the PDE inhibition pattern or PDE’s unre-
ated modes of actions of sildenafil may be responsible for
his interesting difference.
onclusions. The present study is the first to compare the
hort-term hemodynamic profiles of three different PDE5
nhibitors—sildenafil, vardenafil and tadalafil—in a well-
efined patient collective suffering from chronic PAH.
lthough vardenafil showed the most rapid onset of effects,
his substance lacked selectivity for the pulmonary circula-
ion, which was demonstrated for sildenafil and tadalafil,
ven at high doses of the latter agent. The pulmonary
asodilatory response to tadalafil appeared to be the most
ong-lasting, as anticipated from previous studies in the field
f erectile dysfunction. By contrast with sildenafil, vard-
nafil and tadalafil did not improve arterial oxygenation.
bviously, we cannot translate short-term effects into long-
erm effects, because we know that long-term effects may be
ignificantly more efficacious than short-term effects, such as
as been observed with epoprostenol; however, the converse
ay also occur. These findings thus strongly support the
otion that careful evaluation of the pulmonary hemody-
amic and gas exchange effects of each new PDE inhibitor
ocusing on cGMP decay is to be undertaken, despite
ommon classification as PDE5 inhibitors.
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